BensaAPrevitaliDSangiorgioA, et al. PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration. Am J Sports Med. 2025;53(3):745-754.
2.
Dohan EhrenfestDMRasmussonLAlbrektssonT.Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158-167.
3.
GajewskiBJHartSBergquist-UlloaD, et al. Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials. Stat Med. 2019;38(17):3123-3138.
4.
GiustiID’AscenzoSMancòA, et al. Platelet concentration in platelet-rich plasma affects tenocyte behavior in vitro. Biomed Res Int. 2014;2014:630870.
5.
HarrisonP.The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1895-1900.
6.
MacdougallJ. Analysis of dose-response studies: Emax model. In: TingN, ed. Dose Finding in Drug Development. Springer; 2006:127-145.
7.
MurrayIRGeeslinAGGoudieEB, et al. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): platelet-rich plasma and mesenchymal stem cells. J Bone Joint Surg Am. 2017;99(10):809-819.
8.
SaltzmanBMLerouxTMeyerMA, et al. A greater platelet dose may yield better clinical outcomes for platelet-rich plasma in the treatment of knee osteoarthritis: a systematic review. Arthroscopy. 2025;41(3):809-817.e2.
